Related Experiment Videos
[Depression during interferon therapy in chronic hepatitis C patients--a prospective study]
T Otsubo1, H Miyaoka, K Kamijima
1Department of Psychiatry, Showa University School of Medicine.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica
|January 1, 1997
Summary
Interferon (IFN) therapy for chronic active hepatitis C can lead to depression in over a third of patients. Early monitoring and intervention are crucial for managing psychiatric complications during IFN treatment.
Area of Science:
- Hepatology
- Psychiatry
- Clinical Pharmacology
Background:
- Interferon (IFN) therapy is widely used for chronic active hepatitis C.
- Depression is a significant psychiatric complication of IFN therapy, often leading to treatment discontinuation.
Observation:
- A prospective study assessed the psychiatric status of 85 patients undergoing IFN therapy for chronic active hepatitis C.
- Patients were evaluated using DSM-III-R criteria and the Hamilton Depression Scale (HDS) before and at several time points during therapy.
Findings:
- 37.3% of patients developed major depressive episodes during IFN therapy.
- Mean HDS scores increased significantly during treatment, indicating worsening depressive symptoms.
- Patients experiencing depression during therapy showed higher neuroticism, more severe pre-existing mood and sleep disturbances, and a tendency for comorbid conditions.
Implications:
- Careful consideration is needed when deciding on IFN therapy for chronic active hepatitis C.
- Early detection and vigilant monitoring for depression are essential during IFN treatment.
- Proactive management of psychiatric complications can improve treatment adherence and outcomes.